Loading...
In a large previously published study of patients with recent strokes or transient ischemic attacks (TIAs), dipyridamole plus aspirin reduced 2-year risk for all major vascular events by 22% compared with aspirin alone (J Neurol Sci 1996; 143:1); however, four smaller studies showed no such benefit, and the combination of dipyridamole plus aspirin seems to have no advantage over aspirin alone after other types of vascular events.
In this new multinational trial, researchers randomized more than 2700 patients (mean age, 63; 66% male) with TIAs or minor ischemic strokes within the previous 6 months to receive daily aspirin (30–325 mg) with or without dipyridamole (200 mg twice daily). No placebo was given, and the distribution of aspirin dosag…